Use of vap-1 inhibitors for treating fibrotic conditions
WO2010146236A1
Urea substituted sulphonamide derivatives
FI20075278A0
Novel completely human anti-VAP-1 monoclonal antibodies
FI20075258A0
Procedure for selling responders for integrin inhibitors
FI20055498A0
Sulfonamides
FI20055496A0
Modulators that bind to the alpha-1 domain of collagen receptors
AU2004241060A1
Crystalline VAP-1 and uses thereof
WO2005090297A1
Sulphonamide derivatives
WO2004065400A1
Novel binding epitopes for helicobacter pylori and use thereof
AU2003276307A1
High affinity receptors for helicobacter pylori and use thereof
AU2003255544A1
Tumor specific oligosaccharide epitopes and use thereof
TW200500465A
Novel humanized anti-vap-1 monoclonal antibody
AU2003201619A1
Novel binding epitopes for helicobacter pylori and use thereof
PL368612A1
Method of treating alcoholism or alcohol abuse
CZ20031809A3
Glucuronyl-C5-epimerase, DNA encoding thereof and method for its use
US2003125360A1
Carbocyclic hydrazino inhibitors of copper-containing amine oxidases
HU0301625A2
1,3,4-oxadiazine-compounds as inhibitors of copper-containing amine oxidases, process for their preparation and their use for preparation of pharmaceutical compositions
US6492344B1
Syndecan enhancer element and syndecan stimulation of cellular differentiation